Tactile Medical (TCMD) Q4 2025 earnings review
Broad-Based Acceleration Caps a Turnaround Year
Tactile Medical delivered a standout fourth quarter, with total revenue growth accelerating to 21% YoY, well above the 17% pace in Q3 and 8% in Q2. The growth was dual-pronged: the Airway Clearance segment continued its hyper-growth (+66%), while the core Lymphedema segment surged 16%, proving the sales force restructuring earlier in 2025 has paid off. Profitability improved alongside volume, with gross margins hitting 78%. However, FY26 guidance implies a significant deceleration (8-11% growth) compared to the Q4 exit velocity, suggesting management is retaining a conservative stance.
🐂 Bull Case
Lymphedema revenue grew 16% YoY in Q4, a massive improvement from the -3% contraction seen in Q1. The segment added $12.4M in incremental sales, validating the sales force expansion and productivity initiatives.
The airway clearance business (AffloVest) grew 66% YoY. While off a smaller base, it now accounts for 14% of total revenue (up from 10% a year ago) and serves as a potent growth engine.
🐻 Bear Case
Despite exiting 2025 with 21% growth, FY26 guidance calls for only 8-11% growth. This suggests Q4 may have benefited from one-time budget flushes or that management sees headwinds (like tougher comps) emerging.
Operating expenses jumped 20% YoY to $62.2M. While revenue outpaced this slightly (+21%), the company is spending aggressively to capture growth, limiting near-term operating leverage.
⚖️ Verdict: 🟢🟢
Bullish. TCMD has successfully executed a 'U-shaped' recovery in 2025. With zero debt, expanding margins (78%), and both business lines firing, the setup is strong. The conservative FY26 guidance appears to be a 'beat and raise' setup rather than a warning signal.
Key Themes
Airway Clearance Becomes Material
Accelerating. The Airway Clearance segment (AffloVest) is no longer just a niche; it generated $14.1M in Q4 (+66% YoY). This segment has grown from 10% of revenue in Q4'24 to 14% in Q4'25. The continued high growth rate suggests strong market share gains and effective DME channel partnerships.
Lymphedema Segment Turnaround Complete
Accelerating. After a rocky start to 2025 (Q1 -3%), the Lymphedema business has accelerated sequentially every quarter, culminating in +16% YoY growth in Q4. This confirms that the sales force reorganization and CRM implementation issues from H1 are fully resolved.
Gross Margin Expansion
Accelerating. Gross margin hit 78% in Q4, up significantly from 75% in the prior year and 76% in Q3. This expansion drove a 26% increase in Gross Profit dollars. Management previously cited lower manufacturing and warranty costs as drivers; this trend demonstrates pricing power and operational efficiency.
Acquisition of LymphaTech
Tactile acquired LymphaTech for $6.8M upfront. This adds 3D body measurement technology to the portfolio. While the purchase price is small relative to cash holdings, the tech is strategic: it replaces manual tape measurements with digital 3D scans, potentially speeding up the fitting/ordering process and reducing return rates for garments.
Conservative 2026 Guidance
Decelerating. FY26 Revenue is guided to $357-$365M (8-11% growth) and Adjusted EBITDA to $49-51M. Given Q4 revenue grew 21% and Adjusted EBITDA grew 41%, the forward guidance implies a sharp moderation in momentum. This may be prudent expectation setting, but it contrasts with the current trajectory.
Other KPIs
Accelerating. Up 41% YoY from $16.2M. The margin expanded to 22.1% (from 18.9% in Q4'24), demonstrating that despite high OpEx growth, revenue volume and gross margin expansion are dropping to the bottom line.
Stable/Improving. The company fully repaid its $26.3M term loan and repurchased $26.5M in stock during 2025. Despite these outflows, they ended with a fortress balance sheet. The new acquisition ($6.8M) is easily funded.
Accelerating. OpEx grew 20% YoY. This is a watch item. While necessary for growth (sales force, R&D), expenses are growing almost as fast as revenue (21%), limiting operating leverage.
Guidance
Decelerating. The midpoint ($361M) implies 9.6% YoY growth. This is a slowdown from the 21% growth recorded in Q4 2025 and the 12% total growth for FY 2025.
Accelerating. The midpoint ($50M) implies ~11% growth over FY 2025's $44.8M. This suggests EBITDA margins will remain roughly flat or expand slightly (approx 13.8% margin at midpoint vs 13.6% in FY25).
Key Questions
Guidance Conservatism
Revenue growth exited the year at 21%. Why is the FY26 guidance set at only 8-11%? Are there specific headwinds or tough comps (specifically in Airway Clearance) anticipated in H1 2026?
Lymphedema Commercial Durability
Lymphedema revenue swung from -3% in Q1 to +16% in Q4. Is this 16% level a sustainable new run-rate driven by the larger sales force, or was Q4 aided by a backlog flush or budget timing?
Acquisition Integration
How quickly will LymphaTech's 3D scanning technology be deployed to the field sales force, and what is the expected impact on gross margin (via reduced returns) or SG&A efficiency?